AFT Pharmaceuticals develops innovative products that improve health outcomes and provide convenience for healthcare providers and patients. By identifying opportunities others miss, we fill market gaps with solutions that deliver positive health outcomes.

AFT proudly presents Combogesic® IV (also known as Comboval®, Cetafen®, and Maxigesic®), a non-opioid pain management solution combining paracetamol 1000mg and ibuprofen 300mg in a 100mL infusion. Combogesic® IV provides healthcare professionals with a clinically proven, effective, and safe alternative for pain management¹.

Backed by robust clinical evidence¹, Combogesic® IV demonstrates both efficacy and tolerability, making it an advanced choice for pain management.

EU/UK registered. Visit us at the conference or explore our website to learn more.

¹Daniels, S. E., Playne, R., Stanescu, I., Zhang, J., Gottlieb, I. J., & Atkinson, H. C. (2019). Efficacy and Safety of an Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination After Bunionectomy: a Randomized, Double-blind, Factorial, Placebo-controlled Trial. Clinical Therapeutics, 41(10), 1982–1995.e8.

Visit Website:  https://doi.org/10.1016/j.clinthera.2019.07.008